Clinical trials recruiting in Dortmund, Germany

Phase breakdown

Conditions recruiting in Dortmund, Germany

Recruiting trials in Dortmund, Germany

• A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
  NCT07060807 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis
  NCT05344469 · Phase: Not specified · Ages: 18 Years to 100 Years · Sex: All (male and female)
• A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence
  NCT06830720 · Phase: Not specified · Ages: 18 Years to 100 Years · Sex: All (male and female)
• A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in Adults With Type 2 Diabetes
  NCT07112339 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female)
• A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
  NCT06435429 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
  NCT06561386 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
  NCT07361510 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS)
  NCT06780150 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
  NCT07753993 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe
  NCT05363319 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Anatomical Resection of Liver MetAstases iN patIents With RAS-mutated Colorectal Cancer
  NCT04678583 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• Cataract Surgery in Conjunction With Ab-interno Canaloplasty Compared to Cataract Surgery Only in Patients With Mild to Moderate Primary Open-Angle Glaucoma
  NCT05564091 · Phase: Not applicable (e.g. observational or device study) · Ages: 55 Years and older · Sex: All (male and female)
• Comparison of LAA-Closure vs Oral Anticoagulation in Patients With NVAF and Status Post Intracranial Bleeding.
  NCT04298723 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer
  NCT06207734 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female
• EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
  NCT06531824 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
  NCT07064473 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
  NCT07037433 · Phase: Phase 3 · Ages: 45 Years to 99 Years · Sex: All (male and female)
• IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
  NCT06112314 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC
  NCT07242352 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• PROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFS
  NCT05792150 · Phase: Not specified · Ages: 18 Years to 60 Years · Sex: Female
• Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
  NCT05232916 · Phase: Phase 3 · Ages: 18 Years to 100 Years · Sex: All (male and female)
• REdo Transcatheter Aortic VALVE Implantation for the Management of Transcatheter Aortic Valve Failure
  NCT06557798 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer
  NCT06517719 · Phase: Not specified · Ages: 18 Years to 99 Years · Sex: Male
• Sterile Allogeneic Spongioflex® Allograft as Partial Meniscal Replacement After Incomplete Meniscal Loss
  NCT06376422 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 60 Years · Sex: All (male and female)
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
  NCT05633654 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis
  NCT07039110 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Study to Assess Real Life Effectiveness of Foslevodopa/Foscarbidopa in Adult German Participants at Initial Stages of Advanced Parkinson's Disease (EARLY-FOS)
  NCT06916507 · Phase: Not specified · Ages: 18 Years to 64 Years · Sex: All (male and female)
• The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
  NCT05973786 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
  NCT05973851 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• The Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
  NCT05958875 · Phase: Phase 4 · Ages: 18 Years to 70 Years · Sex: All (male and female)
• Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
  NCT07181109 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Dortmund, Germany?

31 recruiting trials have at least one study site in Dortmund, Germany.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.